Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
1.05
USD
|
-6.25%
|
|
+6.06%
|
+42.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
167.9
|
122.5
|
76.65
|
18.53
|
12.46
|
17.82
|
-
|
-
|
Enterprise Value (EV)
1 |
178.4
|
101.5
|
76.65
|
18.53
|
12.46
|
17.82
|
17.82
|
17.82
|
P/E ratio
|
-3.15
x
|
-2.64
x
|
-1.93
x
|
0.4
x
|
-0.57
x
|
-1.11
x
|
-1.12
x
|
-1.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
73.4
x
|
22.6
x
|
27.2
x
|
10.5
x
|
19.1
x
|
26.1
x
|
7.12
x
|
1.44
x
|
EV / Revenue
|
73.4
x
|
22.6
x
|
27.2
x
|
10.5
x
|
19.1
x
|
26.1
x
|
7.12
x
|
1.44
x
|
EV / EBITDA
|
-31,95,825
x
|
-31,32,844
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-30,72,261
x
|
-30,35,816
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-4.05
x
|
-1.9
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,979
|
4,941
|
6,841
|
8,198
|
16,952
|
16,969
|
-
|
-
|
Reference price
2 |
42.20
|
24.80
|
11.20
|
2.260
|
0.7350
|
1.050
|
1.050
|
1.050
|
Announcement Date
|
16/03/20
|
15/03/21
|
10/03/22
|
30/03/23
|
06/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.289
|
5.416
|
2.818
|
1.771
|
0.651
|
0.6825
|
2.504
|
12.33
|
EBITDA
|
-52.54
|
-39.11
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.2
|
-40.96
|
-35.96
|
-36.63
|
-16.89
|
-20.77
|
-20.39
|
-17.55
|
Operating Margin
|
-2,368.06%
|
-756.33%
|
-1,276.26%
|
-2,068.49%
|
-2,594.32%
|
-3,042.86%
|
-814.44%
|
-142.33%
|
Earnings before Tax (EBT)
1 |
-53.24
|
-40.38
|
-35.09
|
47.77
|
-10.29
|
-25.1
|
-24.69
|
-18.29
|
Net income
1 |
-53.24
|
-40.38
|
-35.1
|
42.33
|
-18.4
|
-20.16
|
-21.14
|
-18.75
|
Net margin
|
-2,325.91%
|
-745.55%
|
-1,245.53%
|
2,390.12%
|
-2,825.96%
|
-2,954.58%
|
-844.26%
|
-152.07%
|
EPS
2 |
-13.40
|
-9.400
|
-5.800
|
5.720
|
-1.290
|
-0.9500
|
-0.9400
|
-0.7750
|
Free Cash Flow
|
-54.65
|
-40.36
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-2,387.51%
|
-745.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
15/03/21
|
10/03/22
|
30/03/23
|
06/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
1.862
|
0.002
|
0.442
|
0.57
|
0.507
|
0.252
|
-
|
0.253
|
0.117
|
0.281
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.633
|
-8.175
|
-8.995
|
-13.57
|
-6.632
|
-7.433
|
-5.328
|
-3.969
|
-3.309
|
-4.283
|
-5.2
|
-6.5
|
-7
|
-6.4
|
Operating Margin
|
-463.64%
|
-4,08,750%
|
-2,035.07%
|
-2,381.23%
|
-1,308.09%
|
-2,949.6%
|
-
|
-1,568.77%
|
-2,828.21%
|
-1,524.2%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.375
|
-7.917
|
-8.674
|
70.67
|
-6.739
|
-7.485
|
-8.152
|
-4.425
|
-1.416
|
-4.51
|
-5.2
|
-6.5
|
-7
|
-6.4
|
Net income
1 |
-8.375
|
-7.917
|
-8.674
|
70.66
|
-6.936
|
-7.484
|
-8.152
|
-4.371
|
-1.357
|
-4.517
|
-5.2
|
-6.5
|
-7
|
-6.4
|
Net margin
|
-449.79%
|
-3,95,850%
|
-1,962.44%
|
12,397.02%
|
-1,368.05%
|
-2,969.84%
|
-
|
-1,727.67%
|
-1,159.83%
|
-1,607.47%
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.400
|
-1.200
|
-1.200
|
9.600
|
-0.9400
|
-1.000
|
-0.7500
|
-0.4000
|
-0.0800
|
-0.2500
|
-0.2150
|
-0.2550
|
-0.2200
|
-0.2050
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
10/03/22
|
16/05/22
|
11/08/22
|
14/11/22
|
30/03/23
|
10/05/23
|
10/08/23
|
08/11/23
|
06/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
10.5
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
21
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.1992
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-54.7
|
-40.4
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-10.40
|
-13.10
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-9.030
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
3.47
|
1.86
|
1.83
|
0.36
|
0.1
|
-
|
-
|
-
|
Capex / Sales
|
151.59%
|
34.25%
|
64.83%
|
20.55%
|
15.36%
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
15/03/21
|
10/03/22
|
30/03/23
|
06/03/24
|
-
|
-
|
-
|
Last Close Price
1.05
USD Average target price
5.125
USD Spread / Average Target +388.10% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.86% | 17.82M | | +5.31% | 70.44B | | +10.97% | 8.94B | | -16.83% | 4.75B | | +43.48% | 4.5B | | +3.20% | 3.85B | | +18.82% | 2.38B | | -21.36% | 2.34B | | -29.67% | 2.2B | | +8.38% | 1.96B |
Specialty & Advanced Pharmaceuticals
|